Schizophrenia (SCZ) is a psychiatric disorder characterized by a wide range of positive,
negative and cognitive symptoms, along with an increased risk of metabolic syndrome and …

Prescription rates of second-generation antipsychotics (SGAs) are rapidly increasing for non-indicated
(ie, off-label) usage. SGAs used for approved indications are associated with …

Individuals with intellectual and developmental disabilities are additionally burdened by an
increased risk of metabolic comorbidities. 1–3 A contributing factor to this risk is the high rate …

Disturbed eating behaviours have been widely reported in psychotic disorders since the
early 19th century. There is also evidence that antipsychotic (AP) treatment may induce binge …

Introduction: Clozapine remains the most effective antipsychotic for treatment-refractory
schizophrenia. However, ~40% of the patients respond insufficiently to clozapine. Clozapine’s …

… Nicolette Stogios was involved in all aspects of data collection from patient charts, statistical
analysis, synthesis of results, and writing of this manuscript. Kateryna Maksyutynska was …

Purpose of Review Weight gain is a disconcerting issue experienced by patients treated
with antipsychotics (APs). This review summarizes current knowledge on the prevalence, …

Schizophrenia (SCZ) is a severe mental disorder with high morbidity and lifetime disability
rates. Patients with SCZ have a higher risk of developing metabolic comorbidities such as …

Background Aberrant brain insulin signaling has been posited to lie at the crossroads of
several metabolic and cognitive disorders. Intranasal insulin (INI) is a non-invasive approach …

… Emily Smith and Nicolette Stogios were involved in the systematic search, screening of
articles, extraction of data, risk of bias assessment and the statistical analysis. Emily Au, Kateryna …